GENTAMICIN SULFATE OINTMENT USP, 0.1%

Manufacturer
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
Effective date
2014-02-05
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-02 01:37:27

Label at a glance#

ProductGentamicin sulfate
Active ingredientGENTAMICIN
Label structure11 sections

Indications and uses

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Ge...

Dosage and administration

A small amount of Gentamicin Sulfate Ointment should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

For Dermatologic Use Only
Not For Ophthalmic Use

DESCRIPTION:

DESCRIPTION SECTION

Gentamicin Sulfate Ointment is a wide spectrum antibiotic preparation for topical administration. Each gram contains 1.0 mg of Gentamicin in a base of White Petrolatum with Methylparaben and Propylparaben as preservatives.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Ointment may clear infections that have not responded to treatment with other topical antibiotic agents. In primary skin infections such as impetigo contagiosa, treatment 3 or 4 times daily with Gentamicin Sulfate Ointment usually clears the lesions promptly. In secondary infections, Gentamicin Sulfate Ointment aids in the treatment of the underlying dermatoses by controlling the infection. Bacteria susceptible to the action of gentamicin sulfate include sensitive strains of Streptococci (group A beta-hemolytic, alpha-hemolytic), Staphylococcus aureus (coagulase positive, coagulase negative, and some penicillinase-producing strains), and the gram-negative bacteria, Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Proteus vulgaris, and Kiebsiella pneumoniae.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

This drug product is contraindicated in individuals with a history of sensitivity to any of its components.

PRECAUTIONS:

PRECAUTIONS SECTION

The use of topical antibiotics occasionally allows overgrowth of nonsusceptible organisms, including fungi. If this condition occurs, or if irritation, sensitization or superinfection develops, treatment with gentamicin sulfate should be discontinued and appropriate therapy instituted.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

In patients with dermatoses treated with gentamicin sulfate, irritation (erythema and pruritis) that did not usually require discontinuance of treatment has been reported in a small percentage of cases. There was no evidence of irritation or sensitization, however, in any of these patients patch-tested subsequently with gentamicin sulfate on normal skin. Possible photosensitization has been reported in several patients but could not be elicited in these patients by reapplication of gentamicin sulfate followed by exposure to ultraviolet radiation.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

A small amount of Gentamicin Sulfate Ointment should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. Infected stasis ulcers have responded well to treatment with gentamicin sulfate under gelatin packing.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Gentamicin Sulfate Ointment USP, 0.1% is supplied in 15 gram tubes NDC 0168-0078-15.

Store at controlled room temperature 15°-30°C (59°-86°F).

E. FOUGERA & CO.
A division of
Fougera
PHARMACEUTICALS INC.
Melville, New York 11747

I27815D
R12/11
#292

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15G CONTAINER

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0168-0078-15

Fougera®

GENTAMICIN
SULFATE OINTMENT
USP, 0.1%

Rx only

FOR EXTERNAL USE ONLY.
NOT FOR OPHTHALMIC USE.

NET WT 15 grams

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15G CONTAINER
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15G CONTAINER

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15G CARTON

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0168-0078-15

Fougera ®

GENTAMICIN SULFATE
OINTMENT USP, 0.1%

Rx only

FOR EXTERNAL USE ONLY.
NOT FOR OPHTHALMIC USE.

NET WT 15 grams

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15G CARTON
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15G CARTON

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
0168-0078-152024-07-05C16284748780-19d75b9d0-fa36-f424-e053-dadaa90a57ceGENTAMICIN SULFATE OINTMENT USP, 0.1%
0168-0078-152020-01-31C16284748780-19d75b9d0-fa36-f424-e053-dadaa90a57ceGENTAMICIN SULFATE OINTMENT USP, 0.1%

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
GENTAMICINACTIVE INGREDIENTT6Z9V48IKG3
GENTAMICINACTIVE MOIETYT6Z9V48IKG3
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T3
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U3
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OH3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0168-00780168-0078-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 165 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHDROPS / AURICULAR (OTIC)NAExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / INTRAVENOUS0.13 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION/ DROPS / OPHTHALMIC0.01 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / SUBCUTANEOUS22 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHTABLET, EXTENDED RELEASE / ORAL0.12 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SUSPENSION / INTRAMUSCULAR1 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TELIXIR / ORAL800 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR0.4 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCONCENTRATE / ORAL12 mgExact identifier — unii candidate
79 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USUPPOSITORY / VAGINAL27 mgExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TLOTION / TOPICAL351 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / IRRIGATION2 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM, AUGMENTED / TOPICAL2 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / INTRAVENOUS6 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSHAMPOO, SUSPENSION / TOPICAL0.15 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / RECTAL0.13 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUPPOSITORY / VAGINALNAExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, EXTENDED RELEASE / ORAL0.17 mgExact identifier — unii candidate
79 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / TOPICAL7275 mgExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUPPOSITORY / VAGINALNAExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / INTRALESIONAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UCREAM / TOPICAL4213 mgExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHDROPS / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TFILM, SOLUBLE / BUCCAL3 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION, CONCENTRATE / ORAL0.2 mg/1mlExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INTRA-ARTICULAR0.24 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / NASAL26 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TENEMA / RECTAL0.18 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / ORAL346 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM / VAGINAL22 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION, SUSPENSION / SUBCUTANEOUS0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR3.6 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHELIXIR / ORAL200 mgExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT, AUGMENTED / TOPICAL81.94 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHPOWDER, FOR SUSPENSION / ORAL8 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / INTRAMUSCULAR0.13 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCONCENTRATE / ORAL2.5 mg/5mlExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9ULOTION / TOPICAL25 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHOINTMENT / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, CHEWABLE / ORAL1.28 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / PARENTERAL30 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUSPENSION / ORAL64 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / TOPICAL216 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCAPSULE, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSYRUP / ORAL81 mgExact identifier — unii candidate
79 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UTABLET, EXTENDED RELEASE / ORAL0.18 mgExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / ORAL100 mgExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USPONGE / TOPICALNAExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INFILTRATION80 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUSPENSION / RECTAL271 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / RESPIRATORY (INHALATION)0.03 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / RECTAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / SUBCUTANEOUS2 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INTRADERMAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TAEROSOL, FOAM / TOPICAL0.16 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / INTRAVENOUS0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062533-001GENTAMICIN SULFATEGENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A062533-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0584e616aacf4f…
2026-08-18 06:07:402026-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0531067a03dcf5…
2025-08-23 18:47 UTC2025-08A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-056a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-052680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-051e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-058072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-054b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0587673890dc5c…
2021-03-12 10:30 UTC2021-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-058869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053f01610625f2…
2019-09-15 20:21 UTC2019-09A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05b00525d2431f…
2019-07-19 19:46 UTC2019-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-056a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-051c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-059b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053f0d92c62455…
2023-05-13 08:27 UTC2023-05A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05053a50430f4f…
2023-01-26 05:58 UTC2023-01A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A062533-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A062533-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062533-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062533-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A062533-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062533-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062533-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062533-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062533-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062533-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062533-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062533-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062533-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062533-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062533-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062533-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062533-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062533-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062533-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062533-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062533-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062533-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062533-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A062533-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062533-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062533-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062533-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A062533-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062533-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062533-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062533-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062533-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062533-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062533-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062533-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062533-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062533-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062533-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062533-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062533-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
6e19c8e8-77d4-4ea7-bbc2-12cd86c29649f986fa2a-e667-452f-be4c-bad8588af5252014-02-05Adverse reactionsExact identifier
spl set id: f986fa2a-e667-452f-be4c-bad8588af525

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.